Categories Earnings, Health Care
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG): Q3 2019 Earnings Snapshot
— AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of 2019, vs. $0.66 per share loss expected
— Revenues dropped to $84.13 million from $122.24 million last year, vs. $88.27 million expected
— Lowered full-year 2019 revenue guidance to $320-$330 million from the earlier outlook of $325-$355 million
— Expects full-year operating loss of $278-$268 million, up from $276 million loss estimated earlier
— Expects adjusted EBITDA loss in the range of $75 million to $65 million for 2019, which is down from the previous forecast of $85-$75 million
Most Popular
Key highlights from Autodesk (ADSK) Q4 2021 earnings results
Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per
Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%
Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus
Virgin Galactic stock tanks on delayed test flight
Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000
